Publications by authors named "Ruben Rizzi"

Claim this Profile
G
Generative AI: a generation-defining shift for biopharma regulatory affairs.
Jon Williams, Donna Boyce, Graziella Collu, Sean Curtis, Ramzi Dagher, Ruben Rizzi

Nat Rev Drug Discov· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of the available safety data for the BNT162b2 COVID-19 vaccine: development, approval, and surveillance of use.
Frank van den Ouweland, Nicola Charpentier, Özlem Türeci, Ruben Rizzi, Claudia Lindemann

Expert Rev Vaccines· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and reactogenicity of the BNT162b2 COVID-19 vaccine: Development, post-marketing surveillance, and real-world data.
Frank van den Ouweland, Nicola Charpentier, Özlem Türeci, Ruben Rizzi, Federico J Mensa

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing variant-adapted COVID-19 vaccines to improve protection against Omicron and other recent variants: a plain language summary.
Shanti Pather, Alexander Muik, Ruben Rizzi, Federico Mensa

Expert Rev Vaccines· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine.
Shanti Pather, Nicola Charpentier, Frank van den Ouweland, Ruben Rizzi, Andrew Finlayson

Vaccine· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A call to adapt the regulation of HLA testing for T cell receptor-based therapeutics.
Miriam Meyer, Andrea Mahr, Joanna Brewer, Volker Daniel, Justine Dell'Aringa, Ruben Rizzi

Nat Rev Drug Discov· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory agilities impacting review timelines for Pfizer/BioNTech's BNT162b2 mRNA COVID-19 vaccine: a retrospective study.
Prisha Patel, Judith C Macdonald, Jayanthi Boobalan, Matthew Marsden, Ruben Rizzi

Front Med (Lausanne)· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical development of variant-adapted BNT162b2 COVID-19 vaccines: the early Omicron era.
Shanti Pather, Alexander Muik, Ruben Rizzi, Federico Mensa

Expert Rev Vaccines· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical development and approval of COVID-19 vaccines.
Ulrich Kalinke, Dan H Barouch, Ruben Rizzi, Eleni Lagkadinou, Özlem Türeci

Expert Rev Vaccines· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IABS/CEPI platform technology webinar: Is it possible to reduce the vaccine development time?
Joris Vandeputte, Melanie Saville, Marco Cavaleri, Martin Friede, Adam Hacker, Ruben Rizzi

Biologicals· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis